18 F-Labeled Amidobenzimidazole Analogue for Visualizing STING Expression in Tumor
Molecular Pharmaceutics · 01.04.2024 · 21 (4) · 1942-1951
DOI: 10.1021/acs.molpharmaceut.3c01201 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 06.03.2024. Verfasst von Jianyang Fang und 11 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Vaccines for Infectious Diseases, Center for Molecular Imaging and Translational Medicine, Xiang An Biomedicine Laboratory Sc…. Hauptthemen laut MEDLINE: Fluorine Radioisotopes, Positron-Emission Tomography, Benzimidazoles, Tumor Microenvironment. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: China National Nuclear Corporation, China Postdoctoral Science Foundation, National Natural Science Foundation of China.
Abstract (Originalsprache)
The stimulator of interferon genes (STING) is pivotal in mediating STING-dependent type I interferon production, which is crucial for enhancing tumor rejection. Visualizing STING within the tumor microenvironment is valuable for STING-related treatments, yet the availability of suitable STING imaging probes is limited. In this study, we developed [18F]AlF-ABI, a novel 18F-labeled agent featuring an amidobenzimidazole core structure, for positron emission tomography (PET) imaging of STING in B16F10 and CT26 tumors. [18F]AlF-ABI was synthesized with a decay-corrected radiochemical yield of 38.0 ± 7.9% and radiochemical purity exceeding 97%. The probe exhibited a nanomolar STING binding affinity (KD = 35.6 nM). Upon administration, [18F]AlF-ABI rapidly accumulated at tumor sites, demonstrating significantly higher uptake in B16F10 tumors compared to CT26 tumors, consistent with STING immunofluorescence patterns. Specificity was further validated through in vitro cell experiments and in vivo blocking PET imaging. These findings suggest that [18F]AlF-ABI holds promise as an effective agent for visualizing STING in the tumor microenvironment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Vaccines for Infectious Diseases, Center for Molecular Imaging and Translational Medicine, Xiang An Biomedicine Laboratory School of Public Health, Xiamen University, 4221-116 Xiang'An South Rd,…
- Department of Nuclear Medicine & Minnan PET Center, The First Affiliated Hospital of Xiamen University, Xiamen 361003, China.
- Theranostics and Translational Research Center, Institute of Clinical Medicine, Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College,…
ORCID-Profile: Xianzhong Zhang, Zhide Guo
Förderung
- China National Nuclear Corporation
- China Postdoctoral Science Foundation
- National Natural Science Foundation of China
- National High-Level Hospital Clinical Research Funding
Zitieren
APA
Fang, J., Zhang, J., Meng, L., Li, H., Xia, D., Wang, Y., Chen, H., Liao, Z., Zhuang, R., Li, Y., Zhang, X., & Guo, Z. (2024). 18 F-Labeled Amidobenzimidazole Analogue for Visualizing STING Expression in Tumor. Molecular Pharmaceutics, 21(4), 1942-1951. https://doi.org/10.1021/acs.molpharmaceut.3c01201
Vancouver
Fang J, Zhang J, Meng L, Li H, Xia D, Wang Y, et al. 18 F-Labeled Amidobenzimidazole Analogue for Visualizing STING Expression in Tumor. Molecular Pharmaceutics. 2024;21(4):1942-1951. doi:10.1021/acs.molpharmaceut.3c01201
BibTeX
@article{Fang2024,
author = {Fang, Jianyang and Zhang, Jingru and Meng, Lingxin and Li, Huifeng and Xia, Dongsheng and Wang, Yaoxuan and Chen, Hao and Liao, Zhenhuan and Zhuang, Rongqiang and Li, Yesen and Zhang, Xianzhong and Guo, Zhide},
title = {18 F-Labeled Amidobenzimidazole Analogue for Visualizing STING Expression in Tumor},
journal = {Molecular Pharmaceutics},
year = {2024},
volume = {21},
number = {4},
pages = {1942--1951},
doi = {10.1021/acs.molpharmaceut.3c01201}
}
EUVIMED